Patients who entered the cohort with a prescription for sulfonylureas and later switched to or added the incretin-based drug were considered as exposed to sulfonylureas from cohort entry to the date of filling the prescription for the incretin-based drug
That's the appropriate way to say, yeah
Patent protection serves an important purpose in the pharmaceutical industry by providing incentives for companies to invest in expensive drug development
Most discussions separate the two peptides into complementary roles: BPC-157 is commonly framed around connective tissue support, inflammation reduction, and gut-related repair pathways, while TB-500 is commonly framed around systemic repair signaling and cell migration
Some peptides are increasingly being prescribed by physicians, even though theyre often labeled as research compounds in other contexts
What hasn't kept pace with that ubiquity is a clear picture of how they actually work and how they're best used